An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. - sprookjes - yvandenbroek - TriplyDB

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

http://www.wikidata.org/entity/Q30453975

about

Treatment for hepatitis C virus-associated cryoglobulinaemic vasculitis Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma Chronic hepatitis C and liver fibrosis.Burden of disease and cost of chronic hepatitis C infection in Canada The new era of hepatitis C virus therapy Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults Cost-effectiveness of screening for hepatitis C in Canada.An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment A Canadian screening program for hepatitis C: is now the time?CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study.Chronic hepatitis C genotype 1 virus: who should wait for treatment?A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers.Protease inhibitors for hepatitis C: economic implications.Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database.Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients.HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms.The Second Canadian Symposium on hepatitis C virus: a call to action.The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.Progress in non-invasive detection of liver fibrosis.Hepatitis C virus infection

P2860

Q24188154-554A8E1B-4BCF-4350-9D8D-01916E6811C6 Q24628717-66F4DF6C-8853-48FB-8200-57A97503F7E1 Q26772324-7AA18EBF-3526-466B-B150-8F211264EB0E Q26825671-CA56D750-8382-45BA-AE6D-44F98EA04DB9 Q26849591-3B231B95-23DF-47D9-ADEE-254AD5F47DC8 Q28086947-377D3B71-E711-4967-BDC2-BBAFE9A020B3 Q30435394-8F21FCBE-081A-4465-B6B3-DFBA1896AD08 Q33654457-A64C0EEB-2FC8-4745-842A-A3FCB298CDD4 Q33810118-ECCC6385-6A02-4964-952E-1ECD0AD75084 Q33810973-AE79ABEE-9C87-4880-B85F-83938C6ED2A4 Q34524584-4B6C6D17-D888-46C5-ABA3-C3904305A952 Q34775524-BA898F55-D65F-42BB-9C8F-3DFF320A3214 Q35088460-76D5E83A-2C2B-400D-9034-34838883F50B Q35100139-0EC77F4E-3C2C-458D-878A-30E4A36E5AD4 Q35146790-16E78C1D-9C56-4402-9F3C-4F2718CE0DA7 Q35199268-F196C071-D3F9-4F23-9D9C-97C07FC2B88B Q35241062-3A5C539A-0EEC-445E-8AFA-B5D3B9676C54 Q36761430-F9435E24-0CCF-467C-8064-1375DF2AA2D8 Q36989118-295817BC-009E-4905-A2DF-4567A232B653 Q37100669-918F645F-5233-4569-86EC-F0C70D6F751C Q37229672-298414C6-305F-4A47-B4EB-8CECBAAEB218 Q37525649-4BF83514-F6D5-4485-B030-A49A0FF7ABB8 Q37558564-1C2010D1-1521-4485-BF3B-B45EAAC5742B Q37654449-2462CD5A-1921-4FC2-ACDF-0A4F0278A626 Q37726292-5E36C261-AE6F-4F7F-8093-8AE86DAC6795 Q38120496-2E5CAFD1-6617-4B40-843E-7157CBB231E8 Q38164262-A1014150-A09B-4A1C-9822-99EE813C3FEB Q39214522-A54A0143-53C0-4A84-862D-2B30A2728753 Q39269740-F01E69BD-5B31-4125-9DCD-9C2661368BA7 Q40793633-469A7888-08D1-41B6-8DEE-573715FF37F6 Q40840459-647132D0-E592-45F1-A560-33F6DF7BE1E1 Q42220226-DFE4599E-57B8-43B0-B275-0A2D551F6AE4 Q42922380-13DD0B2C-DEED-4272-A186-60A106903428 Q55288229-9F85E2EA-0CC3-4A3F-ACD4-6CE79070C2DC Q55421930-240CD28A-CFFD-43D5-B972-739DD54C5397 Q56896011-80EDA112-3E71-46B1-ACF5-96C0111D9ABA

P2860

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

http://www.wikidata.org/entity/Q30453975

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

An update on the management of ...... on for the Study of the Liver.

@ast

An update on the management of ...... on for the Study of the Liver.

@en

type

label

An update on the management of ...... on for the Study of the Liver.

@ast

An update on the management of ...... on for the Study of the Liver.

@en

prefLabel

An update on the management of ...... on for the Study of the Liver.

@ast

An update on the management of ...... on for the Study of the Liver.

@en

P1433

Q30453975-19642198-6294-406A-B157-2744A4B622BB

P1476

Q30453975-DAD315EB-EDC5-49C0-941D-217FCD4BE89D

P2093

Q30453975-808BEB4D-0713-48DE-9F2B-04E9414AF97B

Q30453975-81A814A9-AC3D-4909-BAC4-C91DC2E9D1AE

Q30453975-A5051663-A101-49CB-8CD3-F456E7197366

Q30453975-C8C48715-E48D-45FD-A43E-0DB9F78978CD

Q30453975-E30A04B2-D039-464E-8B9E-F7AD461611DF

P2860

Q30453975-0294AF91-95E7-41C5-92E7-0C5D333BB016

Q30453975-042A7FAB-09FD-4213-9196-CD80132D883A

Q30453975-051932F8-BEFA-46E6-8E07-435238CD86D8

Q30453975-0B760DFB-22BC-4861-B71A-9E13529BF4CA

Q30453975-0E8F30B2-AA13-429F-ACD3-C8E41FDE141D

Q30453975-1136C5D5-264C-4752-A61C-8E3E4C37131F

Q30453975-16FDAF04-F2FA-4608-A952-F9FD1141DED0

Q30453975-1D8B82B3-B831-4642-966A-8CD860089986

Q30453975-224F1335-3564-4B5B-A31A-BACFCFEB6671

Q30453975-25A45E4A-B593-4902-B4DC-F713B3C4AB27

P304

Q30453975-9DA4D864-DF01-4B7A-82CF-82AE38A04CF8

P31

Q30453975-5CA48BE6-952A-48DE-A6BD-4374313F9530

P356

Q30453975-AE48B802-9D7A-4F96-A061-66348E161D63

P407

Q30453975-F23626D9-646D-47F8-9A08-5B04411E696A

P433

Q30453975-4737FC1C-6A7F-497F-AFE1-3D1EF2E8B036

P478

Q30453975-31D346F8-68B7-4F37-8618-C01AAAE409CC

P577

Q30453975-04FA8AC4-A662-4A64-8C44-02E473F51B6E

P698

Q30453975-8A63EF9C-82F3-48A3-8495-3DAF6AC9806A

P932

Q30453975-B18D308D-AE5D-4A7B-8197-A1B91BE44F9F

P356

P1433

Canadian Journal of Gastroenterology & Hepatology

P1476

An update on the management of ...... on for the Study of the Liver.

@en

P2093

Alnoor Ramji

http://www.w3.org/2001/XMLSchema#string

Jordan J Feld

http://www.w3.org/2001/XMLSchema#string

Marc Bilodeau

http://www.w3.org/2001/XMLSchema#string

Robert P Myers

http://www.w3.org/2001/XMLSchema#string

Stephen Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Boceprevir for previously treated chronic HCV genotype 1 infection

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Telaprevir for retreatment of HCV infection

P304

359-375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/947676

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22720279

http://www.w3.org/2001/XMLSchema#string

P932

3378284

http://www.w3.org/2001/XMLSchema#string